WuXi Biologics Reports Remarkable 2022 Annual Results
Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to RMB6,724.0 Million Adjusted Net Profit Rose by 47.1% to RMB5,053.9 Million Non-COVID Revenue Achieved 63% Y-o-Y Growth, Strong Momentum Continues into 2023 and Beyond “R” in CRDMO Business…
Comments Off on WuXi Biologics Reports Remarkable 2022 Annual Results